PALO ALTO, Calif., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH™) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH™ technology, and grant a license to Genentech and Roche under Ocera’s related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Help employers find you! Check out all the jobs and post your resume.
